Vernalis Plc (VER) - Financial and Strategic SWOT Analysis Review

October 2017 | 47 pages | ID: V0F77424931EN
GlobalData

Abstracts

Vernalis Plc (VER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. It has operations in Europe and North America. Vernalis is headquartered in Winnersh, the UK.

Vernalis Plc Key Recent Developments

Sep 12,2017: Vernalis: Results Announcement for the year ended 30 June 2017
Jul 18,2017: Vernalis: Year-End Trading Update and Notice of Full Year Results
Apr 26,2017: Servier and Vernalis announce achievement of 3 milestones in their oncology drug discovery collaboration
Apr 21,2017: Vernalis receives a $2 million milestone payment from one of its drug discovery collaborations
Feb 21,2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Vernalis Plc - Key Facts
Vernalis Plc - Key Employees
Vernalis Plc - Key Employee Biographies
Vernalis Plc - Major Products and Services
Vernalis Plc - History
Vernalis Plc - Company Statement
Vernalis Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Vernalis Plc - Business Description
Vernalis Plc - Corporate Strategy
Vernalis Plc - SWOT Analysis
SWOT Analysis - Overview
Vernalis Plc - Strengths
Vernalis Plc - Weaknesses
Vernalis Plc - Opportunities
Vernalis Plc - Threats
Vernalis Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Vernalis Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 12, 2017: Vernalis: Results Announcement for the year ended 30 June 2017
Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results
Apr 26, 2017: Servier and Vernalis announce achievement of 3 milestones in their oncology drug discovery collaboration
Apr 21, 2017: Vernalis receives a $2 million milestone payment from one of its drug discovery collaborations
Feb 21, 2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016
Dec 01, 2016: Vernalis: AGM Statement
Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016
Jul 19, 2016: Vernalis achieves a milestone in its Oncology Collaboration with Servier
Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics
Mar 17, 2016: Vernalis Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Vernalis Plc, Key Facts
Vernalis Plc, Key Employees
Vernalis Plc, Key Employee Biographies
Vernalis Plc, Major Products and Services
Vernalis Plc, History
Vernalis Plc, Subsidiaries
Vernalis Plc, Key Competitors
Vernalis Plc, Ratios based on current share price
Vernalis Plc, Annual Ratios
Vernalis Plc, Annual Ratios (Cont.1)
Vernalis Plc, Interim Ratios
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Vernalis Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Vernalis Plc, Performance Chart (2013 - 2017)
Vernalis Plc, Ratio Charts
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Vernalis Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

UCB SA
Merck & Co Inc
Karessa Pharma Holding AB
Indivior Plc
GW Pharmaceuticals Plc
Grunenthal GmbH
GlaxoSmithKline Plc
AstraZeneca Plc
Amgen Europe BV
Almirall SA